Dermatology Life Quality Index in Patients with Dermatophytosis in a Tertiary Care Centre of Bangladesh.

In our country a huge number of populations are suffering from dermatophytosis. During the last few years, the number of patients affected by dermatophytosis has been increasing. Dermatophytosis tends to be prolonged, recurrent and persistent course which can affect quality of life (QoL). The aim of this study was to seek out the effect of dermatophytosis on the quality of life of the patients of dermatophytosis and to analyze its relationship with various demographic and clinical factors. This was a cross-sectional study in which 306 patients aged ≥16 years with dermatophytosis were included and evaluated for impact of dermatophytosis on quality of life using dermatology life quality index (DLQI) questionnaire. Independent sample t-test and one way ANOVA were used to find out statistical associations between various variables and mean DLQI scores, wherever applicable. The mean DLQI score in this study was 13.07±8.51. Majority (39.5%) subjects had a 'very large' effect on the QoL. Mean DLQI was significantly higher in young subjects, patients with longer duration of disease, more body surface area involved, involvement of more than one sites (generalized involvement) and topical steroid containing preparation users (p<0.05). This study revealed that the quality of life is adversely affected by dermatophytosis. Hence, Steps must be taken for proper counseling and management, along with early detection and elimination of topical steroid use in dermatophytosis.

Systemic Therapy of Dermtophytosis with Voriconaole: A Clinical Observational Study of 250 Bangladeshi Patients.

Superficial fungal infection or dermatophytosis is one of the most common dermatological problems in a tropical country like Bangladesh. For last 4-5 years this skin problem is on rise with increase in cases of recalcitrant, recurrent and chronic dermatophytosis. In place of an easy task to treat dermatophytosis recently it has evolved into difficult to treat by traditional antifungal agents. Meanwhile, voriconazole, primarily appeared as an agent for deep fungal infections, has come out as a new promising systemic antifungal drug for dermatophytosis also. In Bangladesh recently an endeavor has been made to treat superficial fungal infection with voriconazole. Two hundred and ninety four patients suffering from recalcitrant, recurrent, resistant and chronic dermatophytosis between 12 and 70 years of age and both sexes were selected for the study between August 2018 and November 2018 from different parts of the country. Two categories of therapy were designed: Group A - 200mg 12 hourly for 14 days and Group B - 200mg 12 hourly for 28 days. Patients showing full response in 2 weeks were declared apparently cured and were kept under follow up. Those who did not show significant response (less than 50% improvement) in 2 weeks were considered failed. Unresponsive cases after 28 days were considered failed. Both groups were followed up for 4 weeks. Cases not showing any activity of the disease and negative microscopy on two occasions at 2 weeks interval were considered cured. Two hundred and fifty patients completed the study. Incidence of cure rate was more in Group B (93.04%) which is statistically significant (p<0.005). Relapse rate was observed more in Group A (22.83%). Visual side effects were 4.4% while vertigo and headache were observed in 12.0% and 10.8% respectably. Voriconazole is a promising treatment option for recurrent, recalcitrant and chronic dermatophytosis in dosage of 200mg twice daily for at least 4 weeks with negligible side effects. More diversified studies with longer follow up period is required for further opinion to establish an authenticated dosage schedule for treatment of superficial fungal infection.